Gesellschaftsrecht / M&A

Arbeitsrecht und Vergütung für Führungskräfte

Steuern

addex Therapeutics

Homburger News

Share-Image Teamplate Deals-and-Cases

Homburger advised Addex Therapeutics Ltd

On April 3, 2024, Addex Therapeutics, a clinical-stage biopharmaceutical company, listed on the SIX Swiss Exchange and on the Nasdaq, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.
With initial funding of USD 63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix acquired a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex in view of accelerating their development. In return, Addex received CHF 5 million and a 20% equity interest in Neurosterix. Addex will retain its partnerships with Janssen Pharmaceuticals, Inc. and Indivior PLC, as well as unpartnered clinical stage assets including dipraglurant for Parkinson’s disease and post-stroke/TBI recovery as well as its preclinical GABAB positive allosteric modulator (PAM) program for chronic cough.
Homburger advised Addex in this transaction. The Homburger team comprised Frank Gerhard, Romain Fakhoury, Fabio Gasser, Paula Delissen (all Corporate / M&amp;A), Jeremy Reichlin (Employment) and Peter Müller (Tax).

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Regulierung

Wettbewerb

phoenix pharma

Homburger and PHOENIX Pharma Switzerland

After receiving clearance from the Swiss Competition Commission, PHOENIX Pharma Switzerland and the Voigt Group completed the transaction to establish avosano AG, a 50:50 joint venture on April 28, 2023. This closing marks the start of the joint future of Amedis-UE AG, Voigt AG Pharma Grosshandel and Voigt Industrie Service AG under the umbrella of avosano AG. The avosano Group will be an optimally positioned Swiss player in the pharmaceutical wholesale (market share of approx. 35 percent) and prewholesale (market share of approx. 40 percent) with an expected total turnover of approx. CHF 1.7 bn.
Homburger advises PHOENIX Pharma Switzerland on the transaction. The Homburger team is led by Frank Gerhard (Corporate / M&amp;A) and comprises Andreas Burger (Regulatory / Competition) as well as Patrick Schmidt (Corporate / M&amp;A), Allegra Arnold, Daniel Lütolf (both Regulatory / Competition), Angela Casey (Employment), and Fabio Gasser (Corporate / M&amp;A).

Homburger advises PHOENIX Pharma Switzerland on its joint venture with Voigt Group

Technologie und Digitalisierung

IP / IT

Coparion

On October 5, 2021, coparion GmbH &amp; Co KG, a venture capital fund specializing in technology-driven start-ups, together with Ronald Strässler, co-founder of Avaloq, and business angels Hartmut Carl, Stephan Thalmann, Sebastian Amme and Peter Kessel participated in a seed investment round of Veertly SA.
Veertly is a European platform for virtual and hybrid events and digital collaboration. The financing serves to accelerate growth by investing in the areas of sales and marketing as well as in the further development of Veertly&#8217;s product innovations.
Homburger has advised coparion GmbH &amp; Co. KG in its investment.
The Homburger team included partner Andreas Müller (Corporate / M&amp;A, Technology and Digital Economy), lead associate Timo Hasler and junior associates Ferdinand Berthold and Fabio Gasser (all Corporate / M&amp;A), and associate Philippe Baumann (IP / IT, Technology and Digital Economy).

Fabio
Gasser

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Homburger advises PHOENIX Pharma Switzerland on its joint venture with Voigt Group

Homburger advised coparion in the seed investment round of Veertly

Superstar-CEOs – eine Herausforderung für die Corporate Governance, Auch in der Schweiz?

Join the Team

Fabio Gasser

Karriere

Sprachen

Zulassung

Teams

FabioGasser

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Homburger advises PHOENIX Pharma Switzerland on its joint venture with Voigt Group

Homburger advised coparion in the seed investment round of Veertly

Superstar-CEOs – eine Herausforderung für die Corporate Governance, Auch in der Schweiz?

Join the Team

Fabio Gasser

Karriere

Sprachen

Zulassung

Teams

Fabio
Gasser